Melanoma Treatment: Fianlimab and Cemiplimab Study

We are investigating whether combining fianlimab and cemiplimab is safer and more effective than cemiplimab alone for adults with resectable stage III or IV melanoma. This study aims to see how well these treatments work before surgery.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Libtayo
Libtayo is a cancer medicine that helps the immune system find and fight certain advanced skin and lung cancers.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cemiplimab
Cemiplimab is a substance that helps the immune system find and attack certain cancers by blocking a protein that suppresses immune cells.
Retifanlimab
Retifanlimab helps the immune system recognize and attack certain cancers by blocking a protein that suppresses immune responses.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Graz
Dermatology and Venereology
Graz, Austria
Medizinische Universitaet Innsbruck
Department of Dermatology, Venereology and Allergology
Innsbruck, Austria
Noe LGA Gesundheit Region Mitte GmbH
University Hospital St. Poelten, Clinical Department of Dermatology and Venereology
Sankt Pölten, Austria

Sponsor: Regeneron Pharmaceuticals Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.